Screening effects of HCN channel blockers on sleep/wake behavior in zebrafish

Fusun DOLDUR-BALLI[1,*], Brendan KEENAN[1], Amber ZIMMERMAN[1], Olivia J. VEATCH[2], Sandra SMIESZEK[3], Allan I. PACK[1],,

[1]Division of Sleep Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

[2]Department of Psychiatry and Behavioral Sciences, School of Medicine, The University of Kansas Medical Center, Kansas City, KS, USA

[3]Vanda Pharmaceuticals, 2200 Pennsylvania NW, Suite 300-E, Washington, DC, USA

***Correspondence:** fusun.balli@pennmedicine.upenn.edu

Acknowledgements

This study was funded by Vanda Pharmaceuticals.

Conflict of Interest

None.

Animal Studies

Zebrafish experiments were performed in accordance with University of Pennsylvania Institutional Animal Care and Use Committee (IACUC) guidelines (protocol# 806646).

Screening effects of HCN channel blockers on sleep/wake behavior in zebrafish

Abstract: Hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channels generate electrical rhythmicity in various tissues although primarily heart, retina and brain. The HCN channel blocker compound, Ivabradine (Corlanor), is approved by the US Food and Drug Administration (FDA) as a medication to lower heart rate by blocking hyperpolarization activated inward current in the sinoatrial node. In addition, a growing body of evidence suggests a role for HCN channels in regulation of sleep/wake behavior. Zebrafish larvae are ideal model organisms for high throughput drug screening, drug repurposing and behavioral phenotyping studies. We leveraged this model system to investigate effects of three HCN channel blockers (Ivabradine, Zatebradine Hydrochloride and ZD7288) at multiple doses on sleep/wake behavior in wild type zebrafish. Results of interest included shorter latency to sleep at 0.1 μM dose of Ivabradine (ANOVA, p:0.02), moderate reductions in average activity at 30 μM dose of Zatebradine Hydrochloride (ANOVA, p:0.024), and increased sleep at 4.5 μM dose of ZD7288 (ANOVA, p:0.036). These differences support the hypothesis that compounds blocking HCN channels can decrease wakefulness.

Key words: HCN channel blockers, drug screening, sleep/wake, zebrafish, Ivabradine (Corlanor), Zatebradine hydrochloride, ZD7288.

1. Introduction

Hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channels are members of the family of the voltage gated ion channels (Sartiani et al. 2017). HCN channels are encoded by the *HCN1-4* gene family (Chang et al. 2019) and can form homotetramers or heterotetramers with distinct biophysical properties (Sartiani et al. 2017). These integral membrane proteins (Flynn and Zagotta 2018) generate an inward current in heart (I_f) and nerve cells (I_h) (Novella

Romanelli et al. 2016). HCN channels are known as pacemakers (Wobig et al. 2020); they modulate cardiac rhythmicity and neuronal excitability (Wobig et al. 2020). Functions of HCN channels in photoreceptors include adaptation of the vertebrate retina to visual stimuli (Barrow and Wu 2009). Notably, HCN channels are also involved in regulation of sleep/wake behavior (Lewis and Chetkovich 2011; Sartiani et al. 2017; Byczkowicz et al. 2019; Chang et al. 2019) by contributing to the formation of spindle waves (McCormick and Pape 1990; Bal and McCormick 1996) and slow wave oscillations during non-Rapid Eye Movement (REM) sleep (Kanyshkova et al. 2009; Zobeiri et al. 2018). There are different reports on how HCN channels fulfill sleep related functions. One line of research suggests that inhibition of HCN channels, thereby inhibition of I_h current, via local infusion of melatonin in mouse lateral hypothalamus is associated with reductions in wakefulness (Huang, Li, and Leng 2020). In contrast, inhibition of I_h current via orexin A application to mouse prelimbic cortex increased wakefulness (Li et al. 2010). Another study reported sleep fragmentation in a *Drosophila* mutant model, which lacks I_h current; however, no significant difference in total sleep amount was noted between mutant and control flies (Gonzalo-Gomez et al. 2012). These different findings reported in the literature led us to test effects of HCN channel blockers on sleep/wake behavior in zebrafish as they are an ideal vertebrate system for performing high-throughput screening of small molecule compounds. We evaluated Ivabradine, Zatebradine hydrochloride and ZD7288 in this study. Specifically, Ivabradine has been observed to inhibit inward current in human embryonic kidney cell lines, Chinese hamster ovary cell lines and rabbit sinoatrial nodes (Novella Romanelli et al. 2016). Zatebradine inhibited inward current in human embryonic kidney cell lines and Xenopus oocytes (Novella Romanelli et al. 2016). Administration of ZD7288 was found to inhibit

inward current in human embryonic kidney cell lines, Chinese hamster ovary cell lines, Xenopus oocytes, rat dorsal ganglion neurons, spontaneously hypertensive ventricular myocytes and Guinea pig sinoatrial nodes (Novella Romanelli et al. 2016). These compounds block HCN subunits nonselectively (Zhong and Darmani 2021; Novella Romanelli et al. 2016). All three compounds are pharmacological tools used to reduce heart rate (Novella Romanelli et al. 2016); however, Ivabradine is the only FDA approved drug used in patients with heart failure (Novella Romanelli et al. 2016). In this study, we utilized these compounds to block HCN channels, thereby inhibiting I_h current, and studied the effects on sleep in zebrafish larvae.

Drug screening studies using zebrafish models have been instrumental in detecting effects of small molecule compounds on regulation of sleep/wake behavior and circadian rhythm (Rihel et al. 2010; Mosser et al. 2019). In addition, zebrafish are useful for identifying biological targets and biochemical pathways through which drugs exert their functions (Rihel et al. 2010; Mosser et al. 2019; Hoffman et al. 2016). The zebrafish model has several additional advantages, such as yielding a high number of offspring per breeding and high throughput assessment of sleep/wake. It is a diurnal and genetically tractable organism. It serves as a simple vertebrate model that bridges invertebrate and mammalian model organisms (Oikonomou and Prober 2017). Sleep phases and regulation of sleep in zebrafish are conserved and meet all the behavioral criteria that are used to define a sleep state (Rihel, Prober, and Schier 2010; Zhdanova 2006). Given these advantages, to reveal effects of HCN channel blocker compounds on sleep/wake behavior, we tested if wild type zebrafish larvae exposed to three compounds, administered at different dosages, expressed differences in multiple sleep-related traits when compared to vehicle (DMSO) exposed fish.

2. Materials and Methods

2.1. Zebrafish Sleep/Wake Assay

Larval zebrafish were raised on a 14 hour/10 hour light/dark cycle at 28.5°C. The entrainment and activity measurement equipment (ViewPoint Life Sciences Inc., aka Zebraboxes) houses 96 well plates and is continuously illuminated with infrared lights for data acquisition. The equipment is also illuminated with white light for the 14 hour light cycle, followed by 10 hours dark to provide the complete day and night cycle. A constant temperature of 28.5°C is ensured by recirculating water in the chamber of the equipment. Zebrafish larvae collected from a wild type line (AB line) were individually pipetted into each well of a 96 well plate (Whatman, catalog no: 7701-1651) containing 650 µl of standard embryo medium (E3 embryo medium, 5 mM NaCl, 0.17 mM KCl, 0.33 mM $CaCl_2$, 0.33 mM $MgSO_4$, pH 7.4) at 4 days post fertilization. Water levels were topped off each morning once lights were on.

2.2. Drug Testing

Experiments were performed on 96 well plates. Four wells chosen at random (maximum one per row) did not include any larvae but were instead filled with standard embryo medium (E3 embryo medium) to serve as quality control (QC) for the settings, recording and sensitivity of the equipment. Ivabradine (Cayman, Cas Registry No. 148849-67-6), Zatebradine hydrochloride (Tocris, Cas Registry No. 91940-87-3) and ZD7288 (Tocris, Cas Registry No. 133059-99-1) were tested in this study. Each compound was tested at six concentrations varying between 0.1-30 µM (.i.e., 0.1 µM, 0.3 µM, 1.0 µM, 4.5 µM, 10 µM and 30 µM), as reported previously (Rihel et al. 2010). Each drug was dissolved in DMSO. Stock solutions of Ivabradine, Zatebradine hydrochloride and ZD7288 were prepared at 35 millimolar, 40

millimolar and 30 millimolar concentrations, respectively. As indicated by the manufacturers; solubility of Ivabradine and Zatebradine hydrochloride in DMSO is 20 mg/ml and that of ZD7288 is 100 millimolar. Lower concentrations were obtained by serial dilution. Each dose was tested on 11-12 larvae per plate, depending on the location of the randomly chosen QC wells, for evaluating the impact of different doses of the target drug on sleep and behavioral phenotypes. Zebrafish larvae were allowed to acclimate to the environment by spending the first night without any exposure to drugs and baseline sleep was observed during the second night. Drugs were then added at six days post fertilization at 5:00 pm; this was a one-time drug administration. Thus, each assay was performed over a total of four days: acclimation on day 1, tracking baseline sleep on day 2, drug administration on day 3 and data acquisition on days 2-4 (see Figure 1). Concurrently, we studied 11-12 embryos that served as a DMSO (or drug vehicle, 1:1000 vol:vol) exposed control group and 11-12 embryos were exposed to 100 nM (0.1 micromolar) of melatonin as a positive control. Prior literature has utilized this concentration of melatonin to demonstrate sleep-promoting effects (Zhdanova et al. 2001), and our own proof-of-concept data shows that this concentration of melatonin is very effective for increasing sleep in zebrafish larvae (see Supplementary Figure S1). The studies for Ivabradine were repeated six times (three replicates in two Zebraboxes) for a total of 66-72 fish for each drug concentration (11-12 fish per replicate) to ensure robust statistical power. Based on statistical power analysis, providing an effect size of 0.8, appropriate sample size to determine significance was n=25. Therefore, we concluded that three repeats of Zatebradine hydrochloride and ZD7288 assays using a different group of wild type embryos for each replicate would be sufficient by providing three biological replicates for a total of

33-36 fish for each drug concentration (11-12 fish per replicate, all replicates were carried out in the same Zebrabox for each drug).

2.3.Behavioral Phenotyping

Locomotor activity was monitored via a commercially available video tracking system in quantization mode (ViewPoint Life Sciences Inc.) and data were analyzed using a custom designed MATLAB code (Hoffman et al. 2016; Rihel, Prober, and Schier 2010; Lee et al. 2017). Behavioral tracking took place for three days starting from baseline sleep on day 5 of larval development (see Figure 1). The evaluated sleep phenotypes (see Table 1) included total sleep duration, average activity, average waking activity, sleep bout numbers, consolidation of sleep (average sleep bout length) and latency to sleep as a measure relevant to insomnia. Sleep was defined as any one-minute period of inactivity with less than 0.5 second of movement as described previously (Rihel, Prober, and Schier 2010). A sleep bout was defined as a continuous sequence of sleep minutes. Latency to sleep was measured by detecting the length of time starting from lights on (corresponding to daytime sleep) or off (corresponding to nighttime sleep) until the start of the first sleep bout. Total seconds spent swimming per minute was defined as activity. Primary analyses were based on phenotypes calculated within the time window between 30 minutes after drug administration (drug administration was performed at 5:00 pm) and 11 pm (beginning of lights off period). Secondary analyses were performed for the night after drug administration (lights off period).

2.4. Statistical Analysis

Analyses were performed to evaluate phenotypic effects of compounds of interest at six concentrations – 0.1 μM, 0.3 μM, 1.0 μM, 4.5 μM, 10 μM and 30 μM – as reported by Rihel *et al* (Rihel et al. 2010) using complementary approaches. First, to evaluate the relationship

between drug doses and sleep phenotypes with minimal assumptions, we performed an analysis of variance (ANOVA) testing whether there were any differences in phenotypes among the experimental groups (DMSO and drug doses). If results for this overall ANOVA were significant ($p<0.05$), we examined pairwise differences between drug doses and camera-matched DMSO controls to assess which groups were driving the overall differences, including calculation of standardized mean differences (SMDs). The standardized mean difference (SMD) was calculated by dividing the observed mean difference between groups by the pooled standard deviation. As defined by Cohen (Cohen 1988), SMDs of 0.2, 0.5 and 0.8 represent small, medium and large differences, respectively. In addition to ANOVA, two complementary dose-response analyses were performed to evaluate whether a consistent change in sleep phenotypes was observed for increasing drug doses. First, we performed a linear trend analysis, including dose as an ordinal variable in the regression model (e.g., DMSO = 0, 0.1 µM = 1, 0.3 µM = 2, …, 30 µM = 6). This model treats differences between doses as similar in magnitude, asking whether there is a linear increase for higher dosage groups. Second, dose was included as a continuous variable in linear regression, to estimate the expected change in outcome for a 1 µM increase in drug dose; these analyses give increased weight to differences between DMSO and higher dosage groups (e.g. 10 µM or 30 µM). A p-value <0.05 was considered evidence of a significant association across all analyses. To maximize statistical power, analyses were performed pooling data from all experiments. To help account for potential batch effects, the experimental replicate (1, 2 or 3) was included as a covariate and analyses of Ivabradine also included a covariate for experimental box (1 or 2), as two different boxes were utilized. In addition, all analyses performed on data measured after drug administration were adjusted for baseline values of

the given phenotype during the same time period prior (i.e., data from the day before and data from the night before were used as baseline values in primary and secondary analysis, respectively). Analyses in which significant associations in both ANOVA and dose-response analyses are observed were considered the most robust evidence for an effect of the drug compound. Results in which there were observed differences based on ANOVA but not following dose-response analyses were assumed to suggest a single dose of drug may be driving the overall results.

2.5. Power and Sample Size

Our study included between 33-36 larvae per drug concentration across three biological replicates. This represents nearly twice the maximum sample size utilized by a previous zebrafish drug screening study which detected significant effects (Rihel et al. 2010). Furthermore, for pairwise contrasts, ≥33 animals per group were estimated to provide >80% power to detect standardized effect size differences (i.e., Cohen's d) of at least 0.70 at an α=0.05, which represent moderate-large effects. Analyses leveraging all data to examine the linear dose response ($n \approx 240$ total larvae) were well-powered to detect considerably smaller effects, including >90% power for a correlation of 0.21 (equal to 4.4% variance in sleep behavior explained by drug concentration [$R^2 = 0.044$]).

3. Results

3.1. Summary

Visual inspection of plots of sleep/wake phenotypes across Ivabradine, Zatebradine hydrochloride and ZD7288 doses in some experiments suggested characteristics consistent with increased sleep on the day of drug administration. However, any differences observed with these drug compounds were smaller than the effect of melatonin (see Figures 2, 3, and

4). Each drug dose was tested on 33-36 zebrafish larvae in three biological replicates. Results of analyses performed as described in Section 2.4 for each drug are presented in more detail below.

3.2. Statistical Analysis of Ivabradine Screening

3.2.1. Primary Analysis

Primary analyses of phenotypes as calculated within the time window between 30 minutes after Ivabradine administration (drug administration was performed at 5:00 pm) and 11 pm (beginning of the lights off period) are presented in Table 2. In ANOVA comparisons among groups, there was a difference in sleep latency ($p = 0.020$), with a shorter latency in the 0.1 µM group compared to DMSO (SMD = -0.321, $p = 0.048$). No differences in latency were observed between DMSO and other dosage groups, and results of linear and continuous dosage models were non-significant (see Table 2). Near significant differences—following ANOVA—were observed in average activity ($p = 0.094$), and average waking activity ($p = 0.073$). For both endpoints, continuous dosage models suggested some decreased activity for each 1 µM increase in Ivabradine, likely driven by the lower mean value in the 30 µM group. For comparison to differences between DMSO and Ivabradine doses, results of analyses comparing DMSO to the positive control melatonin during the same time period are shown in Supplementary Table S1. Strong differences between DMSO and melatonin were observed for all phenotypes (all $p \leq 0.006$), with absolute standardized mean differences (SMDs) ranging from 0.49 for bout length to 1.15 for average waking activity.

3.2.2. Secondary Analysis

Secondary analysis was performed for sleep phenotypes during the lights off period after Ivabradine administration (Supplementary Table S2). No significant differences among

Ivabradine doses were observed based on ANOVA. A small increase in total sleep was observed in the continuous dosage model, with an increase of 0.71 minutes (95% CI: 0.09, 1.34) sleep for each 1 μM increase in Ivabradine (p = 0.025). Results comparing DMSO and melatonin are again presented as a positive control (Supplementary Table S3). Small to moderate differences were observed with Melatonin in the number (SMD = -0.49, p = 0.002) and length (SMD = 0.38, p = 0.007) of sleep bouts, but there were no differences in total sleep or sleep latency.

3.3. Statistical Analysis of Zatebradine Hydrochloride Screening

3.3.1. Primary Analysis

Comparisons of sleep and activity patterns among drug doses immediately after Zatebradine Hydochloride administration are presented in Table 3. Differences were observed among groups for average activity (p = 0.024) and average waking activity (p = 0.030), but there were no differences in other phenotypes based on ANOVA. Compared to DMSO, the 30 μM dose group showed significantly lower average activity (SMD = -0.43, p = 0.032) and average waking (SMD = -0.40, p = 0.041) activity. These differences are reflected in significant associations in continuous dose models for each phenotype, but only trending results in linear models (Table 3). An association (p = 0.034) in the dosage model was also observed for sleep latency, with each 1 μM increase in Zatebradine Hydochloride associated with a 1.61 minute decrease (95% CI: -3.09, -0.13). We again observed significant differences in all phenotypes when comparing DMSO to melatonin as a positive control (Supplementary Table S4), with absolute SMDs ranging from 0.53 for sleep bout length to 1.42 for average activity and average waking activity.

3.3.2. Secondary Analysis

Secondary analyses were performed for sleep phenotypes in the lights off period after Zatebradine Hydochloride administration (Supplementary Table S5). There were no among group differences based on ANOVA. There was statistically significant ($p = 0.025$) evidence of a small increase in the number of sleep bouts for a 1 μM increase in dosage. There were no differences between DMSO and Melatonin in the lights off period for these phenotypes in this experiment (Supplementary Table S6).

3.4. Statistical Analysis of ZD7288 Screening

3.4.1. Primary Analysis

Comparisons of sleep and activity patterns across doses immediately after ZD7288 administration are presented in Table 4. No differences were observed based on ANOVA results. In dose response analyses of bout length, both the linear model and dosage model indicated longer bouts with increased dose of ZD7288 ($p = 0.021$ and $p=0.005$). The linear model showed an increased bout length of 0.13 minutes per increase in dosage group ($p = 0.021$) and the dosage model showed an increased bout length of 0.03 minutes per 1 μM increase ($p = 0.005$). As in previous experiments, comparisons between DMSO and melatonin as a positive control demonstrated significant differences across all phenotypes (Supplementary Table S7), with absolute SMDs ranging from 0.82 for sleep bout length to 1.52 for the number of sleep bouts.

3.4.2. Secondary Analysis

Secondary analyses were performed for sleep phenotypes in the lights off period after ZD7288 administration (Supplementary Table S8). In ANOVA comparisons, differences among dosage groups were observed for total sleep ($p = 0.036$), number of sleep bouts ($p =$

0.0003) and sleep bout length (p = 0.003); there was a near significant difference in sleep latency (p = 0.064). Interestingly, differences among groups were driven by an increase in total sleep (SMD = 0.53, p = 0.008), decreased number of sleep bouts (SMD = -0.75, p = 0.001), and increased sleep bout length (SMD = 0.54, p = 0.003) within the 4.5 µM group compared to DMSO. In addition, the 10 µM group demonstrated fewer sleep bouts than DMSO (SMD = -0.49, p = 0.023). These associations between sleep phenotypes and moderate doses of ZD7288 are reflected in significant associations in the linear dose response analyses (Supplementary Table S8). There were no differences between DMSO and melatonin for these phenotypes in the lights off period (Supplementary Table S9).

4. Conclusion

We describe the results of experiments evaluating the effects of three drug compounds (Ivabradine [Cayman, Cas Registry No. 148849-67-6], Zatebradine hydrochloride [Tocris, Cas Registry No. 91940-87-3] and ZD7288 [Tocris, Cas Registry No. 133059-99-1]) on sleep/wake behavior of wild type zebrafish larvae in this study. Primary analyses were based on comparisons of phenotypes during the time window 30 minutes after drug administration (drug administration was performed at 5:00 pm) until 11pm (lights off) as well as data on the night following drug administration was used for secondary analyses. Overall, there was modest evidence of these drugs on sleep and wake phenotypes including shorter latency to sleep in the period following drug administration with 0.1 µM of Ivabradine, moderate reductions in average activity in the period following drug administration with 30 µM of Zatebradine Hydrochloride and increased sleep on the night after drug administration for 4.5 µM of ZD7288 compared to DMSO. For Ivabradine and Zatebradine, dosage model was significant for decrease in activity for the time period immediately after drug administration.

Linear model was significant for decrease in activity for the time period immediately after ZD7288 administration. Ultimately, while several specific doses of Ivabradine, Zatebradine hydrochloride or ZD7288 demonstrated some differences compared to DMSO, effects of these compounds was smaller than the effect of Melatonin, a positive control. Although we didn't identify effects of these drugs on sleep/wake behavior as robust as effect of melatonin, there was some evidence that blocking HCN channels has effects on decreasing wakefulness.

5. Discussion

Screening of HCN channel blockers on sleep/wake behavior of zebrafish larvae showed shorter latency to sleep at 0.1 μM dose of Ivabradine, moderate reductions in average activity at 30 μM dose of Zatebradine Hydrochloride, and increased sleep at 4.5 μM dose of ZD7288 as a result of ANOVA analysis in our study. Among these results, reduction in activity following Zatebradine Hydrochoride administration was supported by dosage model and increased sleep following ZD7288 administration was supported by linear model. Waking activity data is utilized to assess health status of the zebrafish larvae in sleep/wake assays (Rihel et al. 2010). We didn't see large changes in waking activity following administration of HCN channel blockers. This indicates that the doses administered were not toxic and zebrafish larvae were healthy during the assessed period of time. There were different reports on effects of blockade of HCN channels such as decreased (Huang, Li and Leng 2020) and increased wakefulness (Li et al., 2010) in mouse models, fragmented sleep (Gonzalo-Gomez et al., 2012) and no change in total sleep duration (Gonzalo-Gomez et al., 2012) in a *Drosophila* model. The differences we found were in support of the reports suggesting that blocking HCN channels decreases wakefulness.

Use of zebrafish as a model organism provided us the opportunity to assess effects of compounds on the whole brain instead of focusing on one brain region at a time (Huang, Li and Leng 2020; Li et al., 2010). Zebrafish is a diurnal organism like humans. This was another advantage of using zebrafish over using a mouse model as mice are nocturnal. *Drosophila* is an invertebrate model (Gonzalo-Gomez et al., 2012). Since zebrafish is a vertebrate model, it possesses more evolutionarily conserved features with mammals compared to *Drosophila* such as nervous system and neuropharmacology (Oikonomou and Prober 2017). Limitations of our model of choice might be due to the method of drug administration. Drug compounds solved in DMSO were pipetted into individual wells of a 96 well plate in which individual larva swims rather than directly administering it such as injecting. However this is the standard method of drug screening in zebrafish (Mosser et al. 2019; Rihel et al. 2010).

Ivabradine does not cross blood brain barrier (Savelieva and Camm 2008). Zatebradine hydrochloride passes blood brain barrier (Kruger et al. 2000). Ability of ZD7288 to pass blood brain barrier is not known (Zhong and Darmani 2021). Blood brain barrier is sealed by day 5 into development in zebrafish (O'Brown, Megason, and Gu 2019). We administered HCN channel blockers to zebrafish larvae at 6 dpf. Thus, we mimicked the conditions of how humans take HCN channel blockers in our study.

Our study was the first report of testing effects of HCN channel blockers in zebrafish to our knowledge. We also displayed and analyzed effects of melatonin in zebrafish larvae. Ivabradine, Zatebradine hydrochloride and ZD7288 do not work selectively on HCN channel subunits (Novella Romanelli et al. 2016). Each HCN channel subunit might be targeted genetically in future studies to dissect the role of each gene in sleep/wake behavior.

References:

Bal, T., and D. A. McCormick. 1996. 'What stops synchronized thalamocortical oscillations?', *Neuron*, 17: 297-308.

Barrow, A. J., and S. M. Wu. 2009. 'Low-conductance HCN1 ion channels augment the frequency response of rod and cone photoreceptors', *J Neurosci*, 29: 5841-53.

Byczkowicz, N., A. Eshra, J. Montanaro, A. Trevisiol, J. Hirrlinger, M. H. Kole, R. Shigemoto, and S. Hallermann. 2019. 'HCN channel-mediated neuromodulation can control action potential velocity and fidelity in central axons', *Elife*, 8.

Chang, X., J. Wang, H. Jiang, L. Shi, and J. Xie. 2019. 'Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels: An Emerging Role in Neurodegenerative Diseases', *Front Mol Neurosci*, 12: 141.

Cohen, Jacob. 1988. *Statistical power analysis for the behavioral sciences.* (Lawrence Erlbaum Associates, Publishers: Hillsdale, NJ).

Flynn, G. E., and W. N. Zagotta. 2018. 'Insights into the molecular mechanism for hyperpolarization-dependent activation of HCN channels', *Proc Natl Acad Sci U S A*, 115: E8086-E95.

Gonzalo-Gomez, A., E. Turiegano, Y. Leon, I. Molina, L. Torroja, and I. Canal. 2012. 'Ih current is necessary to maintain normal dopamine fluctuations and sleep consolidation in Drosophila', *PLoS One*, 7: e36477.

Hoffman, E. J., K. J. Turner, J. M. Fernandez, D. Cifuentes, M. Ghosh, S. Ijaz, R. A. Jain, F. Kubo, B. R. Bill, H. Baier, M. Granato, M. J. Barresi, S. W. Wilson, J. Rihel, M. W. State, and A. J. Giraldez. 2016. 'Estrogens Suppress a Behavioral Phenotype in Zebrafish Mutants of the Autism Risk Gene, CNTNAP2', *Neuron*, 89: 725-33.

Huang, Y., Y. Li, and Z. Leng. 2020. 'Melatonin inhibits GABAergic neurons in the hypothalamus consistent with a reduction in wakefulness', *Neuroreport*, 31: 92-98.

Kanyshkova, T., M. Pawlowski, P. Meuth, C. Dube, R. A. Bender, A. L. Brewster, A. Baumann, T. Z. Baram, H. C. Pape, and T. Budde. 2009. 'Postnatal expression pattern of HCN channel isoforms in thalamic neurons: relationship to maturation of thalamocortical oscillations', *J Neurosci*, 29: 8847-57.

Kruger, C., V. Landerer, C. Zugck, H. Ehmke, W. Kubler, and M. Haass. 2000. 'The bradycardic agent zatebradine enhances baroreflex sensitivity and heart rate variability in rats early after myocardial infarction', *Cardiovasc Res*, 45: 900-12.

Lee, D. A., A. Andreev, T. V. Truong, A. Chen, A. J. Hill, G. Oikonomou, U. Pham, Y. K. Hong, S. Tran, L. Glass, V. Sapin, J. Engle, S. E. Fraser, and D. A. Prober. 2017. 'Genetic and neuronal regulation of sleep by neuropeptide VF', *Elife*, 6: 1-35.

Lewis, A. S., and D. M. Chetkovich. 2011. 'HCN channels in behavior and neurological disease: too hyper or not active enough?', *Mol Cell Neurosci*, 46: 357-67.

Li, B., F. Chen, J. Ye, X. Chen, J. Yan, Y. Li, Y. Xiong, Z. Zhou, J. Xia, and Z. Hu. 2010. 'The modulation of orexin A on HCN currents of pyramidal neurons in mouse prelimbic cortex', *Cereb Cortex*, 20: 1756-67.

McCormick, D. A., and H. C. Pape. 1990. 'Properties of a hyperpolarization-activated cation current and its role in rhythmic oscillation in thalamic relay neurones', *J Physiol*, 431: 291-318.

Mosser, E. A., C. N. Chiu, T. K. Tamai, T. Hirota, S. Li, M. Hui, A. Wang, C. Singh, A. Giovanni, S. A. Kay, and D. A. Prober. 2019. 'Identification of pathways that regulate circadian rhythms using a larval zebrafish small molecule screen', *Sci Rep*, 9: 12405.

Novella Romanelli, M., L. Sartiani, A. Masi, G. Mannaioni, D. Manetti, A. Mugelli, and E. Cerbai. 2016. 'HCN Channels Modulators: The Need for Selectivity', *Curr Top Med Chem*, 16: 1764-91.

O'Brown, N. M., S. G. Megason, and C. Gu. 2019. 'Suppression of transcytosis regulates zebrafish blood-brain barrier function', *Elife*, 8.

Oikonomou, G., and D. A. Prober. 2017. 'Attacking sleep from a new angle: contributions from zebrafish', *Curr Opin Neurobiol*, 44: 80-88.

Rihel, J., D. A. Prober, A. Arvanites, K. Lam, S. Zimmerman, S. Jang, S. J. Haggarty, D. Kokel, L. L. Rubin, R. T. Peterson, and A. F. Schier. 2010. 'Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation', *Science*, 327: 348-51.

Rihel, J., D. A. Prober, and A. F. Schier. 2010. 'Monitoring sleep and arousal in zebrafish', *Methods Cell Biol*, 100: 281-94.

Sartiani, L., G. Mannaioni, A. Masi, M. Novella Romanelli, and E. Cerbai. 2017. 'The Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels: from Biophysics to Pharmacology of a Unique Family of Ion Channels', *Pharmacol Rev*, 69: 354-95.

Savelieva, I., and A. J. Camm. 2008. 'I f inhibition with ivabradine : electrophysiological effects and safety', *Drug Saf*, 31: 95-107.

Wobig, L., T. Wolfenstetter, S. Fechner, W. Bonigk, H. G. Korschen, J. F. Jikeli, C. Trotschel, R. Feederle, U. B. Kaupp, R. Seifert, and T. K. Berger. 2020. 'A family of hyperpolarization-activated channels selective for protons', *Proc Natl Acad Sci U S A*, 117: 13783-91.

Zhdanova, I. V. 2006. 'Sleep in zebrafish', *Zebrafish*, 3: 215-26.

Zhdanova, I. V., S. Y. Wang, O. U. Leclair, and N. P. Danilova. 2001. 'Melatonin promotes sleep-like state in zebrafish', *Brain Res*, 903: 263-8.

Zhong, W., and N. A. Darmani. 2021. 'The HCN Channel Blocker ZD7288 Induces Emesis in the Least Shrew (Cryptotis parva)', *Front Pharmacol*, 12: 647021.

Zobeiri, M., R. Chaudhary, M. Datunashvili, R. J. Heuermann, A. Luttjohann, V. Narayanan, S. Balfanz, P. Meuth, D. M. Chetkovich, H. C. Pape, A. Baumann, G. van Luijtelaar, and T. Budde. 2018. 'Modulation of thalamocortical oscillations by TRIP8b, an auxiliary subunit for HCN channels', *Brain Struct Funct*, 223: 1537-64.

Table 1. Definitions of Key Behavioral Phenotypes in Drug Screening Study

Phenotypes	Definition
Total Sleep	Total sleep in minutes. Sleep is defined as any one-minute period of inactivity with less than 0.5 second of total movement of zebrafish larva.
Sleep Bouts	A continuous sequence of sleep minutes. Total sleep bouts is the bout numbers in a given period.
Sleep Latency	Length of time (in minutes) from lights on or off until the start of the first sleep bout.
Bout Length	Average duration of a sleep bout (in minutes).
Average Activity	Average activity (seconds/minute) calculated by dividing total activity by total recording minutes
Average Waking Activity	Average waking activity (seconds/minute) calculated by dividing total activity by the total waking minutes



Figure 1. Schematic overview of experimental paradigm, including acclimation on experimental day 1 (4 days post fertilization [dpf]), baseline recording on day 2 (5 dpf), drug administration on day 3 (6 dpf) and sleep and behavioral tracking on days 2-4 (5-7 dpf).



Figure 2. Effect of Ivabradine (Corlanor) on sleep of zebrafish larvae. Different final concentrations of this drug compound ranging between 0.1 µM and 30 µM, DMSO control and 0.1 µM melatonin were added to wells containing 6 days post fertilization larvae. Trending but non-significant increase in sleep duration, likely driven by the higher mean value in the 30 µM Ivabradine group can be observed. Melatonin increased sleep immediately after drug administration. 96 well plate was removed from the video monitoring equipment to administer drug compound and software continued to capture activity data. The peak in the sleep graph at the time of drug administration was formed when 96 well plate was removed from the equipment.

Table 2. Sleep and Activity Immediately after Drug Administration across Ivabradine Doses

Phenotype	Adjusted Mean (95% CI)†							ANOVA p‡	Linear Model§		Dosage Model¶	
	DMSO	0.1 µM	0.3 µM	1.0 µM	4.5 µM	10 µM	30 µM		β (95% CI)	p	β (95% CI)	p
Total Sleep, minutes	30.2 (21.8, 38.6)	33.7 (25.3, 42.1)	29.6 (21.3, 37.8)	22.2 (13.7, 30.8)	26.0 (17.6, 34.4)	30.2 (21.9, 38.6)	34.3 (26.0, 42.6)	0.447	0.08 (-1.50, 1.66)	0.924	0.18 (-0.13, 0.49)	0.253
Sleep Bouts, number	13.1 (10.2, 16.1)	14.2 (11.2, 17.1)	12.8 (9.9, 15.7)	11.6 (8.6, 14.6)	10.3 (7.3, 13.2)	13.3 (10.4, 16.2)	15.8 (12.9, 18.7)	0.217	0.13 (-0.43, 0.69)	0.649	0.10 (-0.01, 0.21)	0.073
Sleep Latency, minutes	127.8 (101.2, 154.4)	**89.9 (63.6, 116.3)***	150.8 (124.8, 176.9)	148.6 (121.6, 175.6)	114.8 (88.4, 141.2)	123.6 (97.2, 149.9)	111.4 (85.3, 137.5)	**0.020**	-0.67 (-5.70, 4.36)	0.793	-0.53 (-1.52, 0.458)	0.293
Bout Length, minutes	2.03 (1.74, 2.31)	2.03 (1.76, 2.30)	2.20 (1.91, 2.49)	1.83 (1.52, 2.14)	1.99 (1.71, 2.27)	1.93 (1.64, 2.21)	2.02 (1.75, 2.30)	0.775	-0.015 (-0.068, 0.038)	0.578	-0.001 (-0.011, 0.010)	0.901
Avg. Activity, sec/min	3.26 (3.05, 3.47)	3.27 (3.06, 3.48)	3.40 (3.19, 3.60)	3.33 (3.12, 3.54)	3.37 (3.16, 3.58)	3.22 (3.01, 3.43)	2.96 (2.75, 3.17)	0.094	-0.036 (-0.077, 0.006)	0.094	**-0.012 (-0.020, -0.004)**	**0.003**
Avg. Wake Act., sec/min	3.32 (3.12, 3.53)	3.37 (3.16, 3.58)	3.48 (3.28, 3.68)	3.38 (3.17, 3.59)	3.45 (3.25, 3.65)	3.29 (3.08, 3.49)	3.04 (2.83, 3.24)	0.073	-0.037 (-0.077, 0.004)	0.075	**-0.012 (-0.020, -0.004)**	**0.002**

Statistically significant associations ($p<0.05$) shown in **bold**; †Model estimated mean and 95% confidence interval, adjusted for replicate, experimental box, and baseline values of phenotype; ‡p-value from ANOVA testing whether there are any differences in phenotype among dosage groups; §Results from linear model treating dose as an ordinal variable – β represents the expected change in phenotype associated with increasing to the next highest dosage group; ¶Results from continuous dosage model – β represents the expected change in phenotype for 1 µM increase in dose;*$p<0.05$ compared to DMSO in pairwise comparisons (performed only when ANOVA $p<0.05$).



Figure 3. Effect of Zatebradine hydrochloride on sleep of zebrafish larvae. Different final concentrations of this drug compound ranging between 0.1 µM and 30 µM, DMSO control and 0.1 µM melatonin were added to wells containing 6 days post fertilization larvae. The 30 µM dose group showed significantly lower activity compared to DMSO. Melatonin increased sleep immediately after drug administration. 96 well plate was removed from the video monitoring equipment to administer drug compound and software continued to capture activity data. The peak in the sleep graph at the time of drug administration was formed when 96 well plate was removed from the equipment.

Table 3. Sleep and Activity Immediately after Drug Administration across Zatebradine Hydrochloride Doses

Phenotype	Adjusted Mean (95% CI)†							ANOVA p‡	Linear Model§		Dosage Model¶	
	DMSO	0.1 µM	0.3 µM	1.0 µM	4.5 µM	10 µM	30 µM		β (95% CI)	p	β (95% CI)	p
Total Sleep, minutes	22.8 (11.8, 33.8)	25.2 (14.2, 36.2)	20.5 (9.5, 31.4)	29.1 (18.2, 40.0)	25.0 (14.2, 35.8)	22.3 (11.3, 33.3)	33.3 (22.3, 44.3)	0.714	1.08 (-0.99, 3.14)	0.305	0.28 (-0.126, 0.686)	0.176
Sleep Bouts, number	11.0 (6.6, 15.5)	13.2 (8.7, 17.7)	10.5 (6.0, 15.0)	14.4 (10.0, 18.8)	12.7 (8.3, 17.1)	13.1 (8.6, 17.5)	15.4 (10.8, 19.9)	0.757	0.53 (-0.32, 1.37)	0.220	0.10 (-0.064, 0.273)	0.225
Sleep Latency, minutes	147.0 (107.1, 186.8)	137.5 (97.7, 177.4)	169.7 (129.9, 209.6)	164.2 (125.0, 203.4)	180.1 (140.9, 219.4)	159.1 (119.2, 198.9)	106.4 (66.5, 146.2)	0.183	-2.41 (-9.99, 5.16)	0.531	**-1.61 (-3.087, -0.126)**	**0.034**
Bout Length, minutes	1.85 (1.45, 2.26)	2.07 (1.68, 2.46)	1.97 (1.57, 2.38)	1.86 (1.43, 2.29)	1.75 (1.37, 2.12)	2.14 (1.73, 2.54)	1.62 (1.22, 2.02)	0.560	-0.030 (-0.106, 0.046)	0.434	-0.009 (-0.024, 0.006)	0.228
Avg. Activity, sec/min	3.15 (2.81, 3.48)	3.22 (2.89, 3.56)	3.44 (3.11, 3.78)	3.40 (3.07, 3.73)	3.31 (2.98, 3.64)	3.21 (2.87, 3.54)	**2.62 (2.28, 2.96)***	**0.024**	-0.059 (-0.123, 0.005)	0.072	**-0.022 (-0.035, -0.010)**	**0.001**
Avg. Wake Act., sec/min	3.20 (2.87, 3.52)	3.28 (2.95, 3.61)	3.49 (3.16, 3.82)	3.46 (3.14, 3.79)	3.36 (3.04, 3.69)	3.24 (2.91, 3.57)	**2.71 (2.37, 3.04)***	**0.030**	-0.057 (-0.119, 0.006)	0.078	**-0.021 (-0.034, -0.009)**	**0.001**

Statistically significant associations (p<0.05) shown in **bold**; †Model estimated mean and 95% confidence interval, adjusted for replicate and baseline values of phenotype; ‡p-value from ANOVA testing whether there are any differences in phenotype among dosage groups; §Results from linear model treating dose as an ordinal variable – β represents the expected change in phenotype associated with increasing to the next highest dosage group; ¶Results from continuous dosage model – β represents the expected change in phenotype for 1 µM increase in dose;*p<0.05 compared to DMSO in pairwise comparisons (performed only when ANOVA p<0.05).



Figure 4. Effect of ZD7288 on sleep of zebrafish larvae. Different final concentrations of this drug compound ranging between 0.1 µM and 30 µM, DMSO control and 0.1 µM melatonin were added to wells containing 6 days post fertilization larvae. There is some visual evidence that ZD7288 increased sleep at 4.5 and 30 µM doses after drug was administered but overall ANOVA was not significant. Total sleep was significantly increased at 4.5 µM dose compared to DMSO during lights off period. Melatonin increased sleep immediately after drug administration. 96 well plate was removed from the video monitoring equipment to administer drug compound and software continued to capture activity data. The peak in the sleep graph at the time of drug administration was formed when 96 well plate was removed from the equipment.

Table 4. Sleep and Activity Immediately after Drug Administration across ZD7288 Doses

Phenotype	Adjusted Mean (95% CI)†							ANOVA p‡	Linear Model§		Dosage Model¶	
	DMSO	0.1 µM	0.3 µM	1.0 µM	4.5 µM	10 µM	30 µM		β (95% CI)	p	β (95% CI)	p
Total Sleep, minutes	25.3 (12.7, 38.0)	25.1 (12.2, 38.0)	28.4 (15.7, 41.0)	17.7 (4.8, 30.5)	43.9 (31.1, 56.8)	24.5 (11.7, 37.3)	33.9 (20.4, 47.3)	0.135	1.41 (-1.09, 3.90)	0.268	0.26 (-0.25, 0.76)	0.320
Sleep Bouts, number	12.0 (7.6, 16.5)	10.3 (5.8, 14.8)	13.1 (8.7, 17.5)	11.4 (6.90, 15.95)	20.0 (15.5, 24.5)	11.3 (6.8, 15.7)	11.2 (6.4, 16.0)	0.052	0.24 (-0.65, 1.14)	0.592	-0.05 (-0.24, 0.13)	0.585
Sleep Latency, minutes	95.1 (60.8, 129.4)	132.5 (97.7, 167.3)	106.9 (72.6, 141.2)	133.3 (98.3, 168.2)	94.1 (59.0, 129.3)	125.1 (90.0, 160.1)	84.8 (49.8, 119.9)	0.286	-1.91 (-8.50, 4.68)	0.569	-0.89 (-2.19, 0.42)	0.181
Bout Length, minutes	1.60 (1.01, 2.18)	2.09 (1.46, 2.72)	1.70 (1.12, 2.29)	1.67 (1.03, 2.30)	2.02 (1.47, 2.58)	1.93 (1.28, 2.58)	2.64 (2.12, 3.16)	0.132	**0.128 (0.020, 0.236)**	**0.021**	**0.029 (0.009, 0.049)**	**0.005**
Avg. Activity, sec/min	3.51 (3.18, 3.85)	3.63 (3.29, 3.96)	3.23 (2.91, 3.56)	3.20 (2.88, 3.53)	3.02 (2.69, 3.35)	3.36 (3.04, 3.69)	3.02 (2.68, 3.37)	0.138	**-0.074 (-0.144, -0.004)**	**0.039**	-0.009 (-0.023, 0.004)	0.170
Avg. Wake Act., sec/min	3.58 (3.27, 3.90)	3.70 (3.38, 4.03)	3.31 (3.00, 3.62)	3.25 (2.94, 3.56)	3.14 (2.82, 3.46)	3.40 (3.09, 3.72)	3.13 (2.80, 3.46)	0.167	**-0.071 (-0.138, -0.003)**	**0.040**	-0.008 (-0.021, 0.005)	0.214

Statistically significant associations (p<0.05) shown in **bold**; †Model estimated mean and 95% confidence interval, adjusted for replicate and baseline values of phenotype; ‡p-value from ANOVA testing whether there are any differences in phenotype among dosage groups; §Results from linear model treating dose as an ordinal variable – β represents the expected change in phenotype associated with increasing to the next highest dosage group; ¶Results from continuous dosage model – β represents the expected change in phenotype for 1 µM increase in dose;*p<0.05 compared to DMSO in pairwise comparisons (performed only when ANOVA p<0.05).

Supplementary Figures and Tables



Figure S1. Effect of melatonin on sleep of zebrafish larvae. Three different final concentrations of melatonin (1 nanomolar, 100 nanomolar (0.1 micromolar) and 10 micromolar) and DMSO control were added to the wells containing 6 days post fertilization larvae. a) Sleep graph of 1 hour bins with error bars. b) Sleep graph of 1 hour bins without error bars. There is a robust increase in sleep immediately after melatonin administration at concentrations over 1 nanomolar. n:45 per group. There is no difference in the lights off period with melatonin. This seems to be related to a ceiling effect given the high amounts of sleep in control conditions without melatonin. n: number of animals.

Table S1. Sleep and Activity Immediately After Ivabradine Administration For Melatonin as a Positive Control*

Phenotype	Adjusted Mean (95% CI)†		Difference (95% CI)‡	p§
	DMSO	Melatonin		
Total Sleep, minutes	35.6 (22.1, 49.1)	116.5 (102.9, 130.1)	**80.9 (61.7, 100.1)**	**<0.0001**
Sleep Bouts, number	14.7 (10.4, 19.0)	41.4 (37.1, 45.8)	**26.7 (20.5, 32.8)**	**<0.0001**
Sleep Latency, minutes	121.0 (99.5, 142.5)	21.7 (0.0, 43.4)	**-99.3 (-129.9, -68.7)**	**<0.0001**
Bout Length, minutes	2.04 (1.69, 2.39)	2.73 (2.40, 3.06)	**0.69 (0.21, 1.17)**	**0.006**
Avg. Activity, sec/min	3.22 (3.01, 3.42)	1.28 (1.07, 1.48)	**-1.94 (-2.24, -1.64)**	**<0.0001**
Avg. Wake Act., sec/min	3.30 (3.10, 3.51)	1.35 (1.14, 1.56)	**-1.95 (-2.25, -1.65)**	**<0.0001**

Statistically significant differences ($p<0.05$) shown in **bold**; †Model estimated mean and 95% confidence interval, adjusted for replicate, experimental box, and baseline values of phenotype; ‡Adjusted mean difference and 95% CI between melatonin and DMSO groups; §p-value comparing phenotype between DMSO and Melatonin groups. *These data are from experiments that involved studies of Ivabradine.

Table S2. Sleep during the lights off period after Drug Administration of different doses of Ivabradine and with DMSO as a control

Phenotype	Adjusted Mean (95% CI)†							ANOVA p‡	Linear Model§		Dosage Model¶	
	DMSO	0.1 µM	0.3 µM	1.0 µM	4.5 µM	10 µM	30 µM		β (95% CI)	p	β (95% CI)	p
Total Sleep, minutes	377.5 (360.4, 394.6)	375.2 (358.2, 392.2)	366.6 (349.9, 383.3)	384.4 (367.1, 401.8)	377.5 (360.6, 394.5)	366.5 (349.5, 383.5)	398.9 (382.1, 415.6)	0.118	2.12 (-1.08, 5.33)	0.194	**0.71 (0.09, 1.34)**	**0.025**
Sleep Bouts, number	80.6 (76.9, 84.3)	74.5 (70.8, 78.2)	74.4 (70.7, 78.0)	78.4 (74.6, 82.1)	78.2 (74.6, 81.9)	78.8 (75.1, 82.5)	80.7 (77.1, 84.4)	0.071	0.47 (-0.23, 1.17)	0.185	0.13 (-0.007, 0.267)	0.063
Sleep Latency, minutes	6.86 (6.05, 7.68)	5.77 (4.95, 6.58)	6.26 (5.46, 7.07)	5.67 (4.84, 6.50)	6.84 (6.02, 7.65)	6.90 (6.09, 7.72)	6.41 (5.61, 7.22)	0.160	0.054 (-0.100, 0.208)	0.489	0.010 (-0.021, 0.040)	0.532
Bout Length, minutes	5.02 (4.56, 5.48)	5.29 (4.84, 5.75)	5.32 (4.87, 5.77)	5.15 (4.69, 5.62)	5.20 (4.75, 5.66)	5.05 (4.60, 5.51)	5.58 (5.13, 6.03)	0.678	0.038 (-0.047, 0.124)	0.380	0.012 (-0.005, 0.028)	0.176

Statistically significant associations ($p<0.05$) shown in **bold**; †Model estimated mean and 95% confidence interval, adjusted for replicate, experimental box, and baseline values of phenotype; ‡p-value from ANOVA testing whether there are any differences in phenotype among dosage groups; §Results from linear model treating dose as an ordinal variable – β represents the expected change in phenotype associated with increasing to the next highest dosage group; ¶Results from continuous dosage model – β represents the expected change in phenotype for 1 µM increase in dose;*$p<0.05$ compared to DMSO in pairwise comparisons (performed only when ANOVA $p<0.05$).

Table S3. Sleep during the lights off period after Ivabradine administration for Melatonin as a positive control*

Phenotype	Adjusted Mean (95% CI)†		Difference (95% CI)‡	p§
	DMSO	Melatonin		
Total Sleep, minutes	379.7 (362.9, 396.5)	394.7 (377.7, 411.6)	15.0 (-8.9, 38.8)	0.218
Sleep Bouts, number	81.0 (77.2, 84.8)	72.5 (68.7, 76.3)	**-8.5 (-13.9, -3.1)**	**0.002**
Sleep Latency, minutes	6.75 (5.95, 7.54)	6.50 (5.69, 7.30)	-0.25 (-1.38, 0.89)	0.667
Bout Length, minutes	5.01 (4.53, 5.49)	5.96 (5.47, 6.44)	**0.95 (0.27, 1.63)**	**0.007**

Statistically significant differences ($p<0.05$) shown in **bold**; †Model estimated mean and 95% confidence interval, adjusted for replicate, experimental box, and baseline values of phenotype; ‡Adjusted mean difference and 95% CI between melatonin and DMSO groups; §p-value comparing phenotype between DMSO and Melatonin groups. * These data are from experiments that involved studies of Ivabradine.

Table S4. Sleep and Activity Immediately after Zatebradine Hydrochloride Administration

for Melatonin As a Positive Control*

Phenotype	Adjusted Mean (95% CI)†		Difference (95% CI)‡	p§
	DMSO	Melatonin		
Total Sleep, minutes	20.9 (1.4, 40.3)	108.9 (89.4, 128.3)	**88.0 (60.3, 115.6)**	**<0.0001**
Sleep Bouts, number	11.5 (4.8, 18.2)	42.5 (35.8, 49.2)	**31.0 (21.55, 40.52)**	**<0.0001**
Sleep Latency, minutes	144.1 (110.8, 177.3)	31.7 (-1.5, 65.0)	**-112.4 (-159.5, -65.3)**	**<0.0001**
Bout Length, minutes	1.82 (1.49, 2.15)	2.31 (2.01, 2.61)	**0.49 (0.05, 0.94)**	**0.031**
Avg. Activity, sec/min	3.12 (2.85, 3.38)	1.15 (0.89, 1.41)	**-1.97 (-2.34, -1.59)**	**<0.0001**
Avg. Wake Act., sec/min	3.17 (2.91, 3.43)	1.22 (0.96, 1.48)	**-1.95 (-2.32, -1.58)**	**<0.0001**

Statistically significant differences ($p<0.05$) shown in **bold**; †Model estimated mean and 95% confidence interval, adjusted for replicate and baseline values of phenotype; ‡Adjusted mean difference and 95% CI between melatonin and DMSO groups; §p-value comparing phenotype between DMSO and Melatonin groups.*These data are from experiments that involved studies of Zatebradine Hydrochloride.

Table S5. Sleep during the lights off period after Drug Administration of different doses of Zatebradine Hydrochloride and with DSMO as a control

Phenotype	Adjusted Mean (95% CI)†							ANOVA p‡	Linear Model§		Dosage Model¶	
	DMSO	0.1 µM	0.3 µM	1.0 µM	4.5 µM	10 µM	30 µM		β (95% CI)	p	β (95% CI)	p
Total Sleep, minutes	386.2 (359.3, 413.2)	393.7 (366.4, 421.0)	369.4 (342.5, 396.4)	337.1 (310.5, 363.7)	384.6 (357.9, 411.2)	377.5 (350.6, 404.4)	388.6 (361.7, 415.5)	0.068	-0.25 (-5.45, 4.95)	0.925	0.52 (-0.50, 1.53)	0.319
Sleep Bouts, number	78.2 (73.0, 83.3)	79.0 (73.8, 84.1)	76.0 (70.9, 81.1)	76.7 (71.7, 81.8)	77.1 (72.1, 82.2)	82.8 (77.7, 87.9)	83.3 (78.2, 88.5)	0.264	0.87 (-0.10, 1.83)	0.079	**0.22 (0.03, 0.41)**	**0.025**
Sleep Latency, minutes	7.45 (5.94, 8.97)	8.29 (6.78, 9.81)	7.87 (6.36, 9.38)	8.93 (7.43, 10.44)	7.72 (6.23, 9.22)	7.11 (5.59, 8.62)	7.02 (5.51, 8.53)	0.582	-0.139 (-0.424, 0.146)	0.338	-0.039 (-0.095, 0.016)	0.166
Bout Length, minutes	5.28 (4.63, 5.93)	5.35 (4.69, 6.01)	5.11 (4.47, 5.76)	4.90 (4.26, 5.54)	5.27 (4.63, 5.91)	4.74 (4.09, 5.39)	5.08 (4.43, 5.72)	0.841	-0.059 (-0.181, 0.063)	0.341	-0.005 (-0.029, 0.019)	0.667

Statistically significant associations ($p<0.05$) shown in **bold**; †Model estimated mean and 95% confidence interval, adjusted for replicate and baseline values of phenotype; ‡p-value from ANOVA testing whether there are any differences in phenotype among dosage groups; §Results from linear model treating dose as an ordinal variable – β represents the expected change in phenotype associated with increasing to the next highest dosage group; ¶Results from continuous dosage model – β represents the expected change in phenotype for 1 µM increase in dose;*$p<0.05$ compared to DMSO in pairwise comparisons (performed only when ANOVA $p<0.05$).

Table S6. Sleep during the lights off period after Zatebradine Hydrochloride Administration for Melatonin As a Positive Control*

Phenotype	Adjusted Mean (95% CI)†		Difference (95% CI)‡	p§
	DMSO	Melatonin		
Total Sleep, minutes	382.6 (353.7, 411.5)	358.0 (329.2, 386.9)	-24.6 (-65.6, 16.5)	0.237
Sleep Bouts, number	79.2 (73.8, 84.7)	78.7 (73.2, 84.1)	-0.5 (-8.3, 7.2)	0.892
Sleep Latency, minutes	7.34 (5.44, 9.24)	8.55 (6.65, 10.45)	1.21 (-1.48, 3.90)	0.372
Bout Length, minutes	5.19 (4.65, 5.73)	4.59 (4.05, 5.13)	-0.60 (-1.37, 0.17)	0.123

†Model estimated mean and 95% confidence interval, adjusted for replicate and baseline values of phenotype; ‡Adjusted mean difference and 95% CI between melatonin and DMSO groups; §p-value comparing phenotype between DMSO and Melatonin groups.* These data are from experiments that involved studies of Zatebradine Hydrochloride.

Table S7. Sleep and Activity Immediately after ZD7288 Administration for Melatonin As a Positive Control*

Phenotype	Adjusted Mean (95% CI)†		Difference (95% CI)‡	p§
	DMSO	Melatonin		
Total Sleep, minutes	22.5 (4.6, 40.4)	110.3 (92.4, 128.2)	**87.8 (62.2, 113.3)**	**<0.0001**
Sleep Bouts, number	10.6 (5.7, 15.5)	44.3 (39.4, 49.2)	**33.7 (26.7, 40.7)**	**<0.0001**
Sleep Latency, minutes	94.7 (69.9, 119.5)	12.4 (-12.4, 37.2)	**-82.3 (-117.7, -46.9)**	**<0.0001**
Bout Length, minutes	1.60 (1.24, 1.95)	2.39 (2.07, 2.71)	**0.80 (0.32, 1.28)**	**0.002**
Avg. Activity, sec/min	3.82 (3.50, 4.14)	1.26 (0.94, 1.57)	**-2.56 (-3.03, -2.10)**	**<0.0001**
Avg. Wake Act., sec/min	3.90 (3.59, 4.20)	1.37 (1.07, 1.68)	**-2.52 (-2.97, -2.08)**	**<0.0001**

Statistically significant differences ($p<0.05$) shown in **bold**; †Model estimated mean and 95% confidence interval, adjusted for replicate and baseline values of phenotype; ‡Adjusted mean difference and 95% CI between melatonin and DMSO groups; §p-value comparing phenotype between DMSO and Melatonin groups. *These data are from experiments that involved studies of ZD7288.

Table S8. Sleep during the lights off period after Drug Administration with different doses of ZD7288

Phenotype	Adjusted Mean (95% CI)†							ANOVA p‡	Linear Model§		Dosage Model¶	
	DMSO	0.1 µM	0.3 µM	1.0 µM	4.5 µM	10 µM	30 µM		β (95% CI)	p	β (95% CI)	p
Total Sleep, minutes	356.8 (328.6, 385.0)	340.1 (311.7, 368.5)	371.1 (343.3, 398.8)	374.8 (346.6, 402.9)	**412.1 (383.4, 440.8)***	365.7 (337.6, 393.9)	383.1 (354.8, 411.5)	**0.036**	**5.75 (0.23, 11.27)**	**0.041**	0.56 (-0.52, 1.63)	0.310
Sleep Bouts, number	78.0 (72.7, 83.2)	81.1 (75.8, 86.4)	72.4 (67.1, 77.6)	73.1 (67.8, 78.4)	**64.6 (59.2, 69.9)***	**69.1 (63.8, 74.4)***	77.0 (71.6, 82.3)	**0.0003**	**-1.24 (-2.27, -0.21)**	**0.019**	0.02 (-0.19, 0.22)	0.867
Sleep Latency, minutes	7.12 (5.99, 8.25)	8.11 (6.96, 9.26)	5.63 (4.50, 6.76)	7.12 (5.97, 8.27)	6.05 (4.90, 7.20)	6.44 (5.29, 7.59)	6.38 (5.22, 7.53)	0.064	-0.181 (-0.400, 0.038)	0.104	-0.020 (-0.063, 0.024)	0.378
Bout Length, minutes	5.18 (4.42, 5.95)	4.57 (3.80, 5.34)	5.49 (4.73, 6.25)	5.38 (4.61, 6.15)	**6.87 (6.10, 7.64)***	6.13 (5.36, 6.90)	5.53 (4.76, 6.29)	**0.003**	**0.195 (0.047, 0.343)**	**0.010**	0.012 (-0.017, 0.042)	0.418

†Model estimated mean and 95% confidence interval, adjusted for replicate and baseline values of phenotype; ‡p-value from ANOVA testing whether there are any differences in phenotype among dosage groups; §Results from linear model treating dose as an ordinal variable – β represents the expected change in phenotype associated with increasing to the next highest dosage group; ¶Results from continuous dosage model – β represents the expected change in phenotype for 1 µM increase in dose;*$p<0.05$ compared to DMSO in pairwise comparisons (performed only when ANOVA $p<0.05$).

Table S9. Sleep during the lights off period after ZD7288 Administration for Melatonin As a Positive Control*

Phenotype	Adjusted Mean (95% CI)†		Difference (95% CI)‡	p§
	DMSO	Melatonin		
Total Sleep, minutes	348.3 (318.0, 378.5)	337.5 (307.2, 367.7)	-10.8 (-54.3, 32.7)	0.621
Sleep Bouts, number	80.5 (74.6, 86.4)	78.2 (72.2, 84.1)	-2.3 (-10.7, 6.1)	0.582
Sleep Latency, minutes	7.05 (5.74, 8.36)	7.38 (6.07, 8.69)	0.33 (-1.53, 2.19)	0.728
Bout Length, minutes	4.56 (3.90, 5.22)	4.59 (3.93, 5.26)	0.04 (-0.90, 0.97)	0.939

†Model estimated mean and 95% confidence interval, adjusted for replicate and baseline values of phenotype; ‡Adjusted mean difference and 95% CI between melatonin and DMSO groups; §p-value comparing phenotype between DMSO and Melatonin groups.* These data are from experiments that involved studies of ZD7288.